FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication.
作者信息
Prat Jaime
机构信息
Department of Pathology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
出版信息
J Gynecol Oncol. 2015 Apr;26(2):87-9. doi: 10.3802/jgo.2015.26.2.87.
Abstract
摘要
相似文献
1
FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication.国际妇产科联盟（FIGO）卵巢、输卵管及腹膜癌的分期分类：节略再版
J Gynecol Oncol. 2015 Apr;26(2):87-9. doi: 10.3802/jgo.2015.26.2.87.
2
Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum.国际妇产科联盟（FIGO）卵巢、输卵管及腹膜癌分期分类的节略再版。
Eur J Obstet Gynecol Reprod Biol. 2015 May;188:133-5. doi: 10.1016/j.ejogrb.2015.03.010. Epub 2015 Mar 7.
3
Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum.国际妇产科联盟（FIGO）卵巢、输卵管及腹膜癌分期分类的节略再版。
Eur J Gynaecol Oncol. 2015;36(4):367-9.
4
Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum: Abridged Republication of Guidelines From the International Federation of Gynecology and Obstetrics (FIGO).卵巢、输卵管和腹膜癌的分期分类：国际妇产科联盟（FIGO）指南的节略再版
Obstet Gynecol. 2015 Jul;126(1):171-4. doi: 10.1097/AOG.0000000000000917.
5
[Current FIGO staging classification for cancer of ovary, fallopian tube and peritoneum].[国际妇产科联盟（FIGO）目前关于卵巢癌、输卵管癌和腹膜癌的分期分类]
Ceska Gynekol. 2017 Summer;82(3):230-236.
6
Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum.国际妇产科联盟（FIGO）卵巢、输卵管及腹膜癌分期分类的节略再版。
Cancer. 2015 Oct 1;121(19):3452-4. doi: 10.1002/cncr.29524. Epub 2015 Jun 25.
7
Staging classification for cancer of the ovary, fallopian tube, and peritoneum.卵巢、输卵管及腹膜癌的分期分类
Int J Gynaecol Obstet. 2014 Jan;124(1):1-5. doi: 10.1016/j.ijgo.2013.10.001. Epub 2013 Oct 22.
8
Revised FIGO staging system for cancer of the ovary, fallopian tube, and peritoneum: important implications for radiologists.国际妇产科联盟（FIGO）修订的卵巢、输卵管及腹膜癌分期系统：对放射科医生的重要意义
Jpn J Radiol. 2016 Feb;34(2):117-24. doi: 10.1007/s11604-015-0513-3. Epub 2015 Dec 22.
9
Validation of Revised FIGO Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum Based on a Single Histological Type.基于单一组织学类型的国际妇产科联盟（FIGO）修订版卵巢、输卵管及腹膜癌分期分类的验证
Int J Gynecol Cancer. 2016 Jul;26(6):1012-9. doi: 10.1097/IGC.0000000000000736.
10
The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer.国际妇产科联盟（FIGO）关于卵巢癌、输卵管癌和原发性腹膜癌的新分期系统。
Arch Gynecol Obstet. 2014 Nov;290(5):839-42. doi: 10.1007/s00404-014-3364-8. Epub 2014 Aug 1.
引用本文的文献
1
Executive Summary of the American Radium Society Appropriate Use Criteria for the Management of Peritoneal Carcinomatosis From Different Tumor Origins: Systematic Review and Guidelines.美国镭学会关于不同肿瘤起源的腹膜癌病管理的合理使用标准：系统评价与指南执行摘要
Cancer Med. 2025 Jul;14(14):e71043. doi: 10.1002/cam4.71043.
2
Emerging trends of the tumor microenvironment in peritoneal malignancies (2010-2024): a visualization analysis.腹膜恶性肿瘤中肿瘤微环境的新趋势（2010 - 2024年）：可视化分析
Front Oncol. 2025 Jun 4;15:1515476. doi: 10.3389/fonc.2025.1515476. eCollection 2025.
3
Splenectomy during cytoreductive surgery in advanced epithelial ovarian cancer can be predicted.晚期上皮性卵巢癌细胞减灭术中的脾切除术是可以预测的。
Eur J Obstet Gynecol Reprod Biol X. 2025 May 9;26:100395. doi: 10.1016/j.eurox.2025.100395. eCollection 2025 Jun.
4
Ovarian Cancer-Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors' Molecular Backgrounds.卵巢癌——流行病学、分类、发病机制、治疗及雌激素受体的分子背景
Int J Mol Sci. 2025 May 12;26(10):4611. doi: 10.3390/ijms26104611.
5
Circadian rhythm disruption by PARP inhibitors correlates with treatment toxicity in patients with ovarian cancer and is a predictor of side effects.聚（ADP - 核糖）聚合酶（PARP）抑制剂引起的昼夜节律紊乱与卵巢癌患者的治疗毒性相关，并且是副作用的一个预测指标。
EBioMedicine. 2025 May 16;117:105764. doi: 10.1016/j.ebiom.2025.105764.
6
The Role of Initial Neutropenia and Neutrophil Dynamics in Personalizing Chemotherapy for Platinum-Resistant Ovarian Cancer.初始中性粒细胞减少和中性粒细胞动态变化在铂耐药卵巢癌个体化化疗中的作用
Medicina (Kaunas). 2025 Mar 7;61(3):470. doi: 10.3390/medicina61030470.
7
Serine/threonine kinase 11 (STK11) associated adnexal tumors: from biology to therapeutic impact.丝氨酸/苏氨酸激酶11（STK11）相关附件肿瘤：从生物学特性到治疗意义
Hum Genomics. 2025 Mar 18;19(1):28. doi: 10.1186/s40246-025-00741-w.
8
FLOT1 Is a Novel Serum Biomarker of Ovarian Cancer Targeted by N6-methyladenosine Modification Inhibition.FLOT1是一种受N6-甲基腺苷修饰抑制作用靶向的新型卵巢癌血清生物标志物。
Cell Biol Int. 2025 Jun;49(6):674-691. doi: 10.1002/cbin.70015. Epub 2025 Mar 11.
9
Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux.HER3对CYLD的抑制通过抑制细胞凋亡和诱导药物外排赋予卵巢癌铂耐药性。
Exp Hematol Oncol. 2025 Feb 26;14(1):21. doi: 10.1186/s40164-025-00620-z.
10
Association of pre- and post-diagnosis dietary total antioxidant capacity (TAC) and composite dietary antioxidant index (CDAI) with overall survival in patients with ovarian cancer: a prospective cohort study.卵巢癌患者诊断前后饮食总抗氧化能力（TAC）和复合饮食抗氧化指数（CDAI）与总生存期的关联：一项前瞻性队列研究。
J Transl Med. 2025 Jan 30;23(1):134. doi: 10.1186/s12967-024-06041-6.
本文引用的文献
1
Stage IIIC ovarian/peritoneal serous carcinoma: a heterogeneous group of patients with different prognoses.IIIC期卵巢/腹膜浆液性癌：一组预后各异的异质性患者群体。
Int J Gynecol Pathol. 2014 May;33(3):302-8. doi: 10.1097/PGP.0b013e3182988dfd.
2
Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features.卵巢癌：五种不同起源、遗传改变和临床病理特征的独立疾病。
Virchows Arch. 2012 Mar;460(3):237-49. doi: 10.1007/s00428-012-1203-5. Epub 2012 Feb 10.
3
Ovarian carcinoma pathology and genetics: recent advances.卵巢癌病理学与遗传学：最新进展
Hum Pathol. 2009 Sep;40(9):1213-23. doi: 10.1016/j.humpath.2009.04.017. Epub 2009 Jun 24.
4
Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer.仅通过淋巴结转移分类的 IIIC 期上皮性卵巢癌比其他类型的 IIIC 期上皮性卵巢癌具有更好的预后。
J Gynecol Oncol. 2008 Dec;19(4):223-8. doi: 10.3802/jgo.2008.19.4.223. Epub 2008 Dec 29.
5
Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.因卵巢癌风险降低而接受手术的BRCA阳性女性的原发性输卵管恶性肿瘤。
J Clin Oncol. 2007 Sep 1;25(25):3985-90. doi: 10.1200/JCO.2007.12.2622.
6
Ovarian cancer patients with "node-positive-only" Stage IIIC disease have a more favorable outcome than Stage IIIA/B.仅出现淋巴结转移的IIIC期卵巢癌患者比IIIA/B期患者的预后更好。
Gynecol Oncol. 2007 Oct;107(1):154-6. doi: 10.1016/j.ygyno.2007.05.016. Epub 2007 Jul 5.
7
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.输卵管上皮内癌与盆腔浆液性癌：因果关系的证据。
Am J Surg Pathol. 2007 Feb;31(2):161-9. doi: 10.1097/01.pas.0000213335.40358.47.
8
Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.卵巢癌。《国际妇产科联盟（FIGO）第26届妇科癌症治疗结果年度报告》
Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92. doi: 10.1016/S0020-7292(06)60033-7.
9
Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only?仅根据淋巴结受累情况将患者归类为IIIC期上皮性卵巢癌是否合理？
Gynecol Oncol. 2006 Dec;103(3):797-801. doi: 10.1016/j.ygyno.2006.08.047. Epub 2006 Oct 18.
10
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.系统主动脉和盆腔淋巴结清扫术与仅切除减瘤至最佳状态的晚期卵巢癌肿大淋巴结的比较：一项随机临床试验。
J Natl Cancer Inst. 2005 Apr 20;97(8):560-6. doi: 10.1093/jnci/dji102.
Zotero 插件